Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse.
BACKGROUND
Electrodiagnostic studies (EDX) are not performed routinely before treatment suspension in CIDP, and no data exist regarding their value in predicting clinical relapse.


METHODS
Serial EDX (baseline and after IGIV-C therapy) were analyzed from subjects in the ICE clinical trial who responded to IGIV-C treatment and were subsequently re-randomized to placebo in an extension phase. Comparisons were made between subjects who relapsed and those who did not.


RESULTS
A total of 55% (6/11) of the Relapse group had an increase in total number of demyelinating findings (DF) versus 8% (1/13) in the No Relapse group (P = 0.023). In the Relapse group, 100% had ≥ 1 new DF and 73% (8/11) had ≥ 4 new DF versus 60% (8/13) and 8% (1/13), respectively, in the No Relapse group.


CONCLUSIONS
An increased total number of DF or the occurrence of ≥ 4 new DF may indicate a higher risk of clinical relapse after treatment cessation in IGIV-C-responsive patients.
Weill Cornell Medical College, 1305 York Avenue, Room 217, New York, New York, 10021, USA.
Russell L
RL
Chin
Grifols, Durham, North Carolina, USA.
Chunqin
C
Deng
Toronto General Hospital, Toronto, Ontario, Canada.
Vera
V
Bril
Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Hans-Peter
HP
Hartung
Maastricht University Medical Center, Maastricht and Spaarne Hospital, Hoofdorp, The Netherlands.
Ingemar S J
IS
Merkies
Vanderbilt University, Nashville, Tennessee, USA.
Peter D
PD
Donofrio
Erasmus University Medical Center, Rotterdam, The Netherlands.
Pieter A
PA
Van Doorn
Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Marinos C
MC
Dalakas
Weill Cornell Medical College, 1305 York Avenue, Room 217, New York, New York, 10021, USA.
Norman
N
Latov
D000200:Action Potentials / Q000187:drug effects; D000328:Adult; D000368:Aged; D004568:Electrodiagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects* / Q000502:physiology; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000503:physiopathology / Q000628:therapy*; D011930:Reaction Time; D012008:Recurrence; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors
CIDP; IVIG; NCS; demyelinating criteria; relapse